Image For Activity Cover
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years after PARADIGM-HF (JACC Heart Failure October 2020)
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction, when compared to the gold-standard angiotensin-converting enzyme inhibitor, enalapril.


Christopher O’Connor, MD, FACC

Executive Editor
Mona Fiuzat, PharmD, FACC

JACC Heart Failure CME Editors
Tariq Ahmad, MD, MPH
Adam DeVore, MD
Abhinav Sharma, MD
Mitchell Psotka, MD, PhD
Kishan Parikh, MD

Kieran F. Docherty MBChB
Muthiah Vaduganathan, MD MPH

Important Dates

Date of Release: September 28, 2020
Term of Approval/Date of CME/MOC/ECME Expiration: September 27, 2021

Availability: On-Demand
Available Sep 28, 2020 to Sep 29, 2021
Cost: FREE
Credit Offered: 1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Powered By